Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib + Docetaxel Safety Run-in in Japanese NSCLC
NCT02300298Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2014
- Primary completion
- Jan 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nintedanib in lung adenocarcinoma (LUAD), sponsored by Boehringer Ingelheim. Primary endpoint: Dose Limiting Toxicity. Started Dec 2014; status: completed.
02
Drugs
nintedanib
03
Conditions
lung adenocarcinoma (LUAD)
Beyond the preview
Go deeper on NCT02300298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02300298.